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Introduction {#ehf212499-sec-0004}
============

Cardiogenic shock (CS) is a medical emergency characterized by decreased cardiac output and evidence of inadequate tissue perfusion taken in the presence of adequate cardiac filling pressures. Cardiogenic shock is frequently accompanied by tachycardia and commonly thought to be compensatory in nature. In the presence of cardiac ischaemia and/or structural heart disease, increasing heart rate (HR) leads to increased myocardial oxygen consumption demand and may result in cardiac ischaemia and reduced contractility. However, currently used therapies (rate‐limiting calcium channel blockers and beta‐blockers) directly depress inotropy.[1](#ehf212499-bib-0001){ref-type="ref"}

Pressor therapy, administered to restore tissue perfusion pressure, may further drive tachycardia and contribute to clinical deterioration.

Ivabradine competitively blocks the *IK* ~f~ channel (located only in the sinoatrial node) to reduce sinus HR through deceleration of the gradient of cellular diastolic depolarization without depressing myocardial contractility.[2](#ehf212499-bib-0002){ref-type="ref"} We report outcomes associated with the use of ivabradine to treat sinus tachycardia in a series of patients with CS confirmed by haemodynamic monitoring.[2](#ehf212499-bib-0002){ref-type="ref"}

Aims {#ehf212499-sec-0005}
====

We aim to evaluate the safety and tolerability of ivabradine for HR reduction in CS and whether limitation of peak HR may improve outcomes.

Methods {#ehf212499-sec-0006}
=======

Five patients (four non‐ischaemic and one ischaemic) with severe left ventricular (LV) dysfunction, CS, and sinus tachycardia were invasively monitored during treatment with inotropic and/or vasopressor therapy. Haemodynamic values and mixed venous gases were obtained at baseline, 12, 24, and 48 h.

Results {#ehf212499-sec-0007}
=======

All patients tolerated ivabradine (*Table* [1](#ehf212499-tbl-0001){ref-type="table"}) during the 48 h period. At 24 h after initiation (vs. baseline), we observed a reduction in HR (91.6 ± 6.4 vs. 106 ± 6.8 b.p.m., *P* = 0.04), pulmonary arterial occlusion pressure (24 ± 5 vs. 30 ± 4 mmHg, *P* = 0.04), and right atrial pressure (9 ± 4.3 vs. 17 ± 6 mmHg, *P* = 0.0002). An increase was observed in mixed venous oxygen saturation (SvO~2~) (65 ± 5 vs. 51 ± 9%, *P* \< 0.04), stroke volume (vs. 37 ± 8 mL vs. 49 ± 13 mL, *P* \< 0.04), and right and LV stroke work index (*Table* [1](#ehf212499-tbl-0001){ref-type="table"}). No significant changes were observed with mean arterial pressure or thermodilution‐derived cardiac index. Inotropic support was weaned successfully in all five patients (88 ± 30 h) with subsequent initiation of beta‐blocker therapy. All patients were discharged alive from hospital at 17 ± 7.9 days following ivabradine initiation.

###### 

Patient characteristics and haemodynamic measurement at baseline and with the addition of ivabradine

                                       Patient 1                                                               Patient 2                             Patient 3                             Patient 4                                Patient 5                                     
  ------------------------------------ ----------------------------------------------------------------------- ------------------------------------- ------------------------------------- ---------------------------------------- ------------------------------------ -- -- -- --
  Age (years)                          49                                                                      52                                    46                                    29                                       54                                            
  LVEF (%)                             15                                                                      21                                    24                                    16                                       17                                            
  Pressor type                         Milnirone                                                               Milnirone                             Milnirone                             Milnirone                                Dobutamine                                    
  Pressor duration                     48                                                                      96                                    120                                   Continuous                               Continuous                                    
  ACEi or ARNI or ARB                  Perindopril 4 mg                                                        Enalapril 5 mg b.i.d.                 Perindopril 4 mg                      Perindopril 4 mg                         Enalapril 2.5 mg b.i.d.                       
  Beta‐blocker                         Carvedilol 3.125 mg b.i.d.                                              Carvedilol 3.125 mg b.i.d.            None                                  Carvedilol 3.125 mg b.i.d.               None                                          
  Nitrate                              Nitro patch 0.4 mg                                                      None                                  None                                  Nitro patch 0.2 mg                       None                                          
  Diuretic                             Lasix 40 mg daily                                                       Lasix 40 mg b.i.d.                    Lasix 40 mg daily                     Lasix 80 mg b.i.d.                       Lasix 20 mg                                   
  High‐sensitivity troponin T (ng/L)   78                                                                      17                                    17                                    15                                       10 000                                        
  NT‐proBNP (ng/L)                     5938                                                                    6260                                  3975                                  4274                                     N/A                                           
  Disposition                          Discharged in NYHA II status. Deceased pending primary prevention ICD   Discharged in NYHA II status on OMT   Discharged in NYHA II status on OMT   Currently NYHA IV discharged after VAD   Currently NYHA IV status after VAD            

  Parameter             Baseline (mean ± SD)   6 h (mean ± SD)   12 h (mean ± SD)   24 h (mean ± SD)   48 h (mean ± SD)   *P* value baseline vs. 6 h   *P* value baseline vs. 12 h   *P* value baseline vs. 24 h   *P* value baseline vs. 48 h
  --------------------- ---------------------- ----------------- ------------------ ------------------ ------------------ ---------------------------- ----------------------------- ----------------------------- -----------------------------
  MAP (mmHg)            73.4 ± 7.6             74.2 ± 6.9        75.6 ± 5.4         75.8 ± 5.0         72.4 ± 8.7         0.96                         0.89                          0.81                          0.58
  HR (b.p.m.)           106 ± 8.2              99 ± 7.9          95.4 ± 8.0         91.6 ± 6.4         88.6 ± 6.1         0.64                         0.23                          0.04                          0.004
  SvO~2~ (%)            51.0 ± 8.8             56.8 ± 8.8        63.4 ± 5.4         64.8 ± 5.3         66.6 ± 3.1         0.01                         0.0003                        0.00002                       0.0000002
  RAP (mmHg)            16.8 ± 6.2             10.8 ± 6.0        11.4 ± 5.9         9.0 ± 4.3          9.0 ± 4.9          0.004                        0.007                         0.0003                        0.0003
  PWP (mmHg)            30.4 ± 4.8             26.0 ± 4.9        23.0 ± 3.3         24.0 ± 5.1         23.8 ± 4.6         0.43                         0.02                          0.04                          0.10
  CI (L/min/m^2^)       1.7 ± 0.2              2.1 ± 0.4         2.2 ± 0.4          2.5 ± 0.7          2.6 ± 0.5          0.98                         0.94                          0.62                          0.58
  RVSWI (g·m/m^2^)      5.4 ± 1.7              7.6 ± 3.0         7.2 ± 1.9          7.4 ± 2.8          8.0 ± 2.2          0.26                         0.11                          0.02                          0.003
  LVSWI (g·m/m^2^)      12.2 ± 2.5             13.8 ± 1.9        14.8 ± 3.6         16.4 ± 2.2         17.4 ± 2.8         0.71                         0.12                          0.02                          0.0005
  SV (mL)               37.2 ± 7.6             42.8 ± 9.2        46.0 ± 7.6         49.2 ± 12.9        56.2 ± 11.6        0.33                         0.02                          8.0 × 10^--7^                 6.6 × 10^--12^
  Lactate (mM)          2.42 ± 0.5             1.58 ± 0.6        1.44 ± 0.4         1.08 ± 0.4         0.96 ± 0.2         0.79                         0.72                          0.44                          0.35
  Creatinine (μmol/L)   137.8 ± 16.9           N/A               126.6 ± 16.7       119.2 ± 15.0       110.0 ± 18.0       N/A                          0.08                          3.3 × 10^--4^                 7.6 × 10^--9^
  Temperature (°C)      36.8 ± 0.5             37.0 ± .3         36.9 ± 0.1         37.0 ± 0.2         36.9 ± 0.1         1.00                         1.00                          1.00                          1.00

ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CI, cardiac index; HR, heart rate; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; LVSWI, left ventricular stroke work index; MAP, mean arterial pressure; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; OMT, optimal medical therapy; PWP, pulmonary wedge pressure; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; SV, stroke volume; VAD, ventricular assist device.

Discussion {#ehf212499-sec-0008}
==========

Cardiogenic shock is frequently accompanied by tachycardia thought to be compensatory for maintenance of cardiac output, despite the attendant increasing oxygen costs of work. This is thought to occur via two mechanisms: first, increased frequency of contraction (presumably at similar contractility) leading to a linear increase in cardiac output and, second, through an often‐overlooked phenomenon, the Bowditch--Treppe effect.[3](#ehf212499-bib-0003){ref-type="ref"} This term describes the increased force of contraction that accompanies increased frequency of muscle depolarization. While this phenomenon describes the physiology in normal muscle, the opposite effect has been shown to occur in failing myocardium, where contractility may fall above HRs above 80--100 b.p.m. Early data were predominately derived via animal models; however, more recently, *ex vivo* and *in vivo* human data support an abnormal Bowditch--Treppe effect in humans with systolic LV dysfunction and increased rates of right ventricular pacing, worsening cardiac performance despite a 75% increase in HR.[3](#ehf212499-bib-0003){ref-type="ref"}, [4](#ehf212499-bib-0004){ref-type="ref"}

There is an abundance of evidence regarding HR reduction in chronic heart failure with beta‐blockers, which demonstrate short‐term reduction followed by a longer‐term improvement in myocardial performance.[5](#ehf212499-bib-0005){ref-type="ref"} A case series of patients with severe LV dysfunction (*n* = 10) with pulmonary capillary wedge pressure ≥15 mmHg and sinus tachycardia experienced a 27% reduction in HR without any adverse effects following intravenous ivabradine.[6](#ehf212499-bib-0006){ref-type="ref"} Similarly, Porcile *et al*.[7](#ehf212499-bib-0007){ref-type="ref"} reported on 52 patients with decompensated heart failure (but not in shock) and sinus tachycardia during treatment with dobutamine reported a significant decrease in HR in association with increased stroke volume and without deleterious effects on CO or mean arterial pressure. In each of these studies, stroke volume rose in association with HR reduction as in our series. Indeed, our patients, in clinical and haemodynamic CS, were able to improve stroke volume, belying the notion of a 'fixed' stroke volume in the setting of sinus tachycardia. These benefits may be due to partial reversal of a negative force‐frequency effect in the setting of severe LV systolic dysfunction, possibly in combination with a more favourable oxygen cost of myocardial work.

Ivabradine is well tolerated with a favourable side effect profile, which includes fatigue, symptomatic bradycardia, phosphenes, and a small increase in risk of atrial fibrillation but does not include negative contractility.[6](#ehf212499-bib-0006){ref-type="ref"} We observed no adverse events related to ivabradine in our case series with up to 1 year of follow‐up. Although there are no randomized studies evaluating the use of ivabradine in CS, one prospective study aims to evaluate the use in patients with shock and multiple organ dysfunction syndrome not exclusive to cardiac dysfunction (NCT01186783).

In our small non‐randomized series of patients in CS, ivabradine was safely used to reduce HR in patients previously intolerant of beta‐blockade. Future studies should be undertaken to determine the optimal HR in humans with CS and whether systematic limitation of peak HR may improve outcomes.
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